Literature DB >> 23661698

Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.

Sara Ferluga1, Roy Hantgan, Yehuda Goldgur, Juha P Himanen, Dimitar B Nikolov, Waldemar Debinski.   

Abstract

The EphA2 receptor tyrosine kinase is overexpressed in a number of malignancies and is activated by ephrin ligands, most commonly by ephrin-A1. The crystal structure of the ligand-receptor complex revealed a glycosylation on the Asn-26 of ephrin-A1. Here we report for the first time the significance of the glycosylation in the biology of EphA2 and ephrin-A1. Ephrin-A1 was enzymatically deglycosylated, and its activity was evaluated in several assays using glioblastoma (GBM) cells and recombinant EphA2. We found that deglycosylated ephrin-A1 does not efficiently induce EphA2 receptor internalization and degradation, and does not activate the downstream signaling pathways involved in cell migration and proliferation. Data obtained by surface plasmon resonance confirms that deglycosylated ephrin-A1 does not bind EphA2 with high affinity. Mutations in the glycosylation site on ephrin-A1 result in protein aggregation and mislocalization. Analysis of Eph/ephrin crystal structures reveals an interaction between the ligand's carbohydrates and two residues of EphA2: Asp-78 and Lys-136. These findings suggest that the glycosylation on ephrin-A1 plays a critical role in the binding and activation of the EphA2 receptor.

Entities:  

Keywords:  Crystal Structure; EphA2; Glycosylation; Ligand-binding Protein; Receptor; Receptors; Signaling; ephrin-A1

Mesh:

Substances:

Year:  2013        PMID: 23661698      PMCID: PMC3689987          DOI: 10.1074/jbc.M113.464008

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Signal transfer by eph receptors

Authors: 
Journal:  Cell Tissue Res       Date:  1999-10       Impact factor: 5.249

2.  Crystal structure of an ephrin ectodomain.

Authors:  J Toth; T Cutforth; A D Gelinas; K A Bethoney; J Bard; C J Harrison
Journal:  Dev Cell       Date:  2001-07       Impact factor: 12.270

3.  Crystal structure of an Eph receptor-ephrin complex.

Authors:  J P Himanen; K R Rajashankar; M Lackmann; C A Cowan; M Henkemeyer; D B Nikolov
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 4.  Mechanisms and functions of Eph and ephrin signalling.

Authors:  Klas Kullander; Rüdiger Klein
Journal:  Nat Rev Mol Cell Biol       Date:  2002-07       Impact factor: 94.444

Review 5.  Eph signaling: a structural view.

Authors:  Juha-Pekka Himanen; Dimitar B Nikolov
Journal:  Trends Neurosci       Date:  2003-01       Impact factor: 13.837

6.  Architecture of Eph receptor clusters.

Authors:  Juha P Himanen; Laila Yermekbayeva; Peter W Janes; John R Walker; Kai Xu; Lakmali Atapattu; Kanagalaghatta R Rajashankar; Anneloes Mensinga; Martin Lackmann; Dimitar B Nikolov; Sirano Dhe-Paganon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-26       Impact factor: 11.205

Review 7.  The Eph family of receptors.

Authors:  E B Pasquale
Journal:  Curr Opin Cell Biol       Date:  1997-10       Impact factor: 8.382

8.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

Review 9.  Ephs and ephrins in cancer: ephrin-A1 signalling.

Authors:  Amanda Beauchamp; Waldemar Debinski
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

10.  EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells.

Authors:  Andre M Gobin; James J Moon; Jennifer L West
Journal:  Int J Nanomedicine       Date:  2008
View more
  17 in total

1.  A Case of UDP-Galactose 4'-Epimerase Deficiency Associated with Dyshematopoiesis and Atrioventricular Valve Malformations: An Exceptional Clinical Phenotype Explained by Altered N-Glycosylation with Relative Preservation of the Leloir Pathway.

Authors:  Christopher A Febres-Aldana; Liset Pelaez; Meredith S Wright; Ossama M Maher; Anthony J Febres-Aldana; Jun Sasaki; Parul Jayakar; Anuj Jayakar; Magaly Diaz-Barbosa; Michelin Janvier; Bala Totapally; Daria Salyakina; Jorge R Galvez-Silva
Journal:  Mol Syndromol       Date:  2020-10-29

2.  Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant.

Authors:  Jill W Ivey; Eduardo L Latouche; Megan L Richards; Glenn J Lesser; Waldemar Debinski; Rafael V Davalos; Scott S Verbridge
Journal:  Biophys J       Date:  2017-07-25       Impact factor: 4.033

3.  Integrated Transcriptomic and Glycomic Profiling of Glioma Stem Cell Xenografts.

Authors:  Norelle C Wildburger; Shiyue Zhou; Lauren G Zacharias; Roger A Kroes; Joseph R Moskal; Mary Schmidt; Parvin Mirzaei; Joy Gumin; Frederick F Lang; Yehia Mechref; Carol L Nilsson
Journal:  J Proteome Res       Date:  2015-08-04       Impact factor: 4.466

Review 4.  Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.

Authors:  Erika Gucciardo; Nami Sugiyama; Kaisa Lehti
Journal:  Cell Mol Life Sci       Date:  2014-05-04       Impact factor: 9.261

Review 5.  Asymmetry at cell-cell interfaces direct cell sorting, boundary formation, and tissue morphogenesis.

Authors:  Rosa Ventrella; Nihal Kaplan; Spiro Getsios
Journal:  Exp Cell Res       Date:  2017-03-18       Impact factor: 3.905

Review 6.  Ephs and Ephrins in malignant gliomas.

Authors:  Sara Ferluga; Waldemar Debinski
Journal:  Growth Factors       Date:  2014-11-24       Impact factor: 2.511

Review 7.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

8.  EphA2 is a functional receptor for the growth factor progranulin.

Authors:  Thomas Neill; Simone Buraschi; Atul Goyal; Catherine Sharpe; Elizabeth Natkanski; Liliana Schaefer; Andrea Morrione; Renato V Iozzo
Journal:  J Cell Biol       Date:  2016-11-30       Impact factor: 10.539

9.  Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Authors:  Cassandra L Pegg; Leanne T Cooper; Jing Zhao; Michael Gerometta; Fiona M Smith; Michael Yeh; Perry F Bartlett; Jeffrey J Gorman; Andrew W Boyd
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

10.  Simultaneous targeting of Eph receptors in glioblastoma.

Authors:  Sara Ferluga; Carla Maria Lema Tomé; Denise Mazess Herpai; Ralph D'Agostino; Waldemar Debinski
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.